Cargando…

A quantum chemical approach representing a new perspective concerning agonist and antagonist drugs in the context of schizophrenia and Parkinson’s disease

Schizophrenia and Parkinson’s disease can be controlled with dopamine antagonists and agonists. In order to improve the understanding of the reaction mechanism of these drugs, in this investigation we present a quantum chemical study of 20 antagonists and 10 agonists. Electron donor acceptor capacit...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez, Ana, Ibarra, Ilich A., Vargas, Rubicelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907805/
https://www.ncbi.nlm.nih.gov/pubmed/31830046
http://dx.doi.org/10.1371/journal.pone.0224691
_version_ 1783478601106063360
author Martínez, Ana
Ibarra, Ilich A.
Vargas, Rubicelia
author_facet Martínez, Ana
Ibarra, Ilich A.
Vargas, Rubicelia
author_sort Martínez, Ana
collection PubMed
description Schizophrenia and Parkinson’s disease can be controlled with dopamine antagonists and agonists. In order to improve the understanding of the reaction mechanism of these drugs, in this investigation we present a quantum chemical study of 20 antagonists and 10 agonists. Electron donor acceptor capacity and global hardness are analyzed using Density Functional Theory calculations. Following this theoretical approach, we provide new insights into the intrinsic response of these chemical species. In summary, antagonists generally prove to be better electron acceptors and worse electron donors than dopamine, whereas agonists present an electron donor-acceptor capacity similar to that of dopamine. The chemical hardness is a descriptor that captures the resistance of a chemical compound to change its number of electrons. Within this model, harder molecules are less polarizable and more stable systems. Our results show that the global hardness is similar for dopamine and agonists whilst antagonists present smaller values. Following the Hard and Soft Acid and Bases principle, it is possible to conclude that dopamine and agonists are hard bases while antagonists are soft acids, and this can be related to their activity. From the electronic point of view, we have evolved a new perspective for the classification of agonist and antagonist, which may help to analyze future results of chemical interactions triggered by these drugs.
format Online
Article
Text
id pubmed-6907805
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-69078052019-12-27 A quantum chemical approach representing a new perspective concerning agonist and antagonist drugs in the context of schizophrenia and Parkinson’s disease Martínez, Ana Ibarra, Ilich A. Vargas, Rubicelia PLoS One Research Article Schizophrenia and Parkinson’s disease can be controlled with dopamine antagonists and agonists. In order to improve the understanding of the reaction mechanism of these drugs, in this investigation we present a quantum chemical study of 20 antagonists and 10 agonists. Electron donor acceptor capacity and global hardness are analyzed using Density Functional Theory calculations. Following this theoretical approach, we provide new insights into the intrinsic response of these chemical species. In summary, antagonists generally prove to be better electron acceptors and worse electron donors than dopamine, whereas agonists present an electron donor-acceptor capacity similar to that of dopamine. The chemical hardness is a descriptor that captures the resistance of a chemical compound to change its number of electrons. Within this model, harder molecules are less polarizable and more stable systems. Our results show that the global hardness is similar for dopamine and agonists whilst antagonists present smaller values. Following the Hard and Soft Acid and Bases principle, it is possible to conclude that dopamine and agonists are hard bases while antagonists are soft acids, and this can be related to their activity. From the electronic point of view, we have evolved a new perspective for the classification of agonist and antagonist, which may help to analyze future results of chemical interactions triggered by these drugs. Public Library of Science 2019-12-12 /pmc/articles/PMC6907805/ /pubmed/31830046 http://dx.doi.org/10.1371/journal.pone.0224691 Text en © 2019 Martínez et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Martínez, Ana
Ibarra, Ilich A.
Vargas, Rubicelia
A quantum chemical approach representing a new perspective concerning agonist and antagonist drugs in the context of schizophrenia and Parkinson’s disease
title A quantum chemical approach representing a new perspective concerning agonist and antagonist drugs in the context of schizophrenia and Parkinson’s disease
title_full A quantum chemical approach representing a new perspective concerning agonist and antagonist drugs in the context of schizophrenia and Parkinson’s disease
title_fullStr A quantum chemical approach representing a new perspective concerning agonist and antagonist drugs in the context of schizophrenia and Parkinson’s disease
title_full_unstemmed A quantum chemical approach representing a new perspective concerning agonist and antagonist drugs in the context of schizophrenia and Parkinson’s disease
title_short A quantum chemical approach representing a new perspective concerning agonist and antagonist drugs in the context of schizophrenia and Parkinson’s disease
title_sort quantum chemical approach representing a new perspective concerning agonist and antagonist drugs in the context of schizophrenia and parkinson’s disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907805/
https://www.ncbi.nlm.nih.gov/pubmed/31830046
http://dx.doi.org/10.1371/journal.pone.0224691
work_keys_str_mv AT martinezana aquantumchemicalapproachrepresentinganewperspectiveconcerningagonistandantagonistdrugsinthecontextofschizophreniaandparkinsonsdisease
AT ibarrailicha aquantumchemicalapproachrepresentinganewperspectiveconcerningagonistandantagonistdrugsinthecontextofschizophreniaandparkinsonsdisease
AT vargasrubicelia aquantumchemicalapproachrepresentinganewperspectiveconcerningagonistandantagonistdrugsinthecontextofschizophreniaandparkinsonsdisease
AT martinezana quantumchemicalapproachrepresentinganewperspectiveconcerningagonistandantagonistdrugsinthecontextofschizophreniaandparkinsonsdisease
AT ibarrailicha quantumchemicalapproachrepresentinganewperspectiveconcerningagonistandantagonistdrugsinthecontextofschizophreniaandparkinsonsdisease
AT vargasrubicelia quantumchemicalapproachrepresentinganewperspectiveconcerningagonistandantagonistdrugsinthecontextofschizophreniaandparkinsonsdisease